National Institute of Biomedical Imaging and Bioengineering; Notice of Closed Meeting, 26575 [2015-11063]
Download as PDF
<![CDATA[
Federal Register / Vol. 80, No. 89 / Friday, May 8, 2015 / Notices
Place: National Institutes of Health, 31
Center Drive, Building 31, Conference Room
6, Bethesda, MD 20892.
Closed: 03:00 p.m. to Adjournment.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 31
Center Drive, Building 31, Conference Room
6, Bethesda, MD 20892.
Contact Person: Donna Brooks, Executive
Officer, National Institutes of Health,
National Institute on Minority Health and
Heath Disparities, 6707 Democracy Blvd.,
Suite 800, Bethesda, MD 20892, (301) 435–
2135, brooksd@mail.nih.gov.
Any member of the public interested
in presenting oral comments to the
committee may notify the Contact
Person listed on this notice at least 10
days in advance of the meeting.
Interested individuals and
representatives of organizations may
submit a letter of intent, a brief
description of the organization
represented, and a short description of
the oral presentation. Only one
representative of an organization may be
allowed to present oral comments and if
accepted by the committee,
presentations may be limited to five
minutes. Both printed and electronic
copies are requested for the record. In
addition, any interested person may file
written comments with the committee
by forwarding their statement to the
Contact Person listed on this notice. The
statement should include the name,
address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
instituted stringent procedures for
entrance onto the NIH campus. All
visitor vehicles, including taxis, hotel,
and airport shuttles, will be inspected
before being allowed on campus.
Visitors will be asked to show one form
of identification (for example, a
government-issued photo ID, driver’s
license, or passport) and to state the
purpose of their visit.
Dated: May 4, 2015.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2015–11062 Filed 5–7–15; 8:45 am]
BILLING CODE 4140–01–P
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Biomedical Imaging and Bioengineering
Special Emphasis Panel, SBIR Contract
Review.
Date: June 17, 2015.
Time: 12:00 p.m. to 3:30 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health, Two
Democracy Plaza, Suite 920, 6707 Democracy
Boulevard, Bethesda, MD 20892, (Virtual
Meeting).
Contact Person: Dennis Hlasta, Ph.D.,
Scientific Review Officer, 6707 Democracy
Boulevard, Suite 952, Bethesda, MD 20892,
301–451–4794, hlastadj@mail.nih.gov.
Dated: May 4, 2015.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2015–11063 Filed 5–7–15; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Announcement of Requirements and
Registration for the Opioid Overdose
Prevention Challenge
SAMHSA, HHS.
Notice.
AGENCY:
ACTION:
Authority: 15 U.S.C. 3719.
In summarizing the challenge
that will be issued by your agency,
please answer the following four
questions:
SUMMARY:
asabaliauskas on DSK5VPTVN1PROD with NOTICES
(1) What action is being taken?
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Biomedical
Imaging and Bioengineering; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
VerDate Sep<11>2014
16:38 May 07, 2015
Jkt 235001
The Substance Abuse and Mental
Health Services Administration
(SAMHSA) has issued a challenge to
help prevent opioid overdose and
support recovery through innovative,
software-based solutions that help
people know the signs of opioid use,
understand what to do if a family
member or friend overdoses on heroin
or opioid pain medications, and support
PO 00000
Frm 00054
Fmt 4703
Sfmt 4703
26575
treatment for opioid addiction and
recovery.
(2) Why is this action necessary?
There were 17,000 deaths from
opioids in 2010, double the deaths in
2001. Use of prescription opioids has
quadrupled. Death by opioid overdose is
preventable. SAMHSA hopes to help
prevent deaths from opioid overdose,
and support treatment and recovery for
individuals with an opioid substance
use disorder.
(3) What is the objective of the
challenge?
To prevent deaths from opioid
overdose, and support treatment and
recovery for individuals with an opioid
substance use disorder by providing
resources and information on
understanding the signs of overdose,
how to respond to an overdose,
information about opioid use, treatment,
and recovery.
(4) What is the intended effect of this
action?
A reduction in the number of
individuals dying from opioid overdose.
SAMHSA is seeking solutions to this
problem through cost-effective, portable,
technology-based products that
effectively reach a diverse population of
friends and family concerned about
opioid use by someone they know.
Technology-based products may
include, but are not limited to, web
applications, mobile apps, and Web
sites.
The challenge starts on June 1,
2015 10:00 a.m. ET. The challenge ends
on July 29, 2015 11:59 p.m. ET.
FOR FURTHER INFORMATION CONTACT: Dina
Passman, Public Health Advisor,
SAMHSA/CSAT/PMB, 1 Choke Cherry
Road, Room 5–1070, Rockville, MD,
Phone: (240) 276–2854, Email:
Dina.Passman@samhsa.hhs.gov.
SUPPLEMENTARY INFORMATION:
Subject of Challenge Competition:
Opioid Overdose Prevention.
Eligibility Rules for Participating in
the Competition:
To satisfy the mandatory provisions of
the Competes Act, use the following
language:
‘‘To be eligible to win a prize under
this challenge, an individual or entity—
(1) Shall have registered to participate
in the competition under the rules
promulgated by [the issuing agency];
(2) Shall have complied with all the
requirements under this section;
(3) In the case of a private entity, shall
be incorporated in and maintain a
primary place of business in the United
States, and in the case of an individual,
DATES:
E:\FR\FM\08MYN1.SGM
08MYN1
]]>Agencies
[Federal Register Volume 80, Number 89 (Friday, May 8, 2015)]
[Notices]
[Page 26575]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-11063]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Biomedical Imaging and Bioengineering;
Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Biomedical Imaging and
Bioengineering Special Emphasis Panel, SBIR Contract Review.
Date: June 17, 2015.
Time: 12:00 p.m. to 3:30 p.m.
Agenda: To review and evaluate contract proposals.
Place: National Institutes of Health, Two Democracy Plaza, Suite
920, 6707 Democracy Boulevard, Bethesda, MD 20892, (Virtual
Meeting).
Contact Person: Dennis Hlasta, Ph.D., Scientific Review Officer,
6707 Democracy Boulevard, Suite 952, Bethesda, MD 20892, 301-451-
4794, hlastadj@mail.nih.gov.
Dated: May 4, 2015.
David Clary,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2015-11063 Filed 5-7-15; 8:45 am]
BILLING CODE 4140-01-P
